{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:26:24Z","timestamp":1749191184044},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Kissei Pharmaceutical Co., Ltd."},{"name":"Daiichi Sankyo Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40268-018-0258-4","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T04:06:25Z","timestamp":1546488385000},"page":"47-55","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study"],"prefix":"10.1007","volume":"19","author":[{"given":"Hiroshi","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kubono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Taneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotoshi","family":"Kuramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"258_CR1","first-page":"304","volume":"47","author":"Y Iwasa","year":"2010","unstructured":"Iwasa Y, Mizutani H, Endo H, Kuroyanagi K, Shiozawa T, Nakano Y. Urief capsules (generic name: silodosin) post marketing surveillance\u2014drug use-results survey (article in Japanese). Med Cons New Remed. 2010;47:304\u201317.","journal-title":"Med Cons New Remed"},{"key":"258_CR2","first-page":"763","volume":"50","author":"Y Iwasa","year":"2013","unstructured":"Iwasa Y, Mizutani H, Endo H, Kuroyanagi K, Taneyama T. Urief (generic name: silodosin) post marketing surveillance\u2014specified drug use-results survey on long-term use (article in Japanese). Med Cons New Remed. 2013;50:763\u201375.","journal-title":"Med Cons New Remed"},{"key":"258_CR3","volume-title":"Clinical guideline for benign prostatic hyperplasia","author":"The Japanese Urological Association","year":"2011","unstructured":"Association The Japanese Urological. Clinical guideline for benign prostatic hyperplasia. Tokyo: RichHill Medical Inc.; 2011."},{"key":"258_CR4","first-page":"1663","volume":"27","author":"Y Iwasa","year":"2014","unstructured":"Iwasa Y, Taneyama T, Takahashi H, et al. Searching for background factors influencing the improvement effect of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia\u2014analysis of two post-marketing surveillance studies (article in Japanese). Jpn J Urol Surg. 2014;27:1663\u201370.","journal-title":"Jpn J Urol Surg"},{"key":"258_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","volume":"98","author":"K Kawabe","year":"2006","unstructured":"Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019\u201324.","journal-title":"BJU Int"},{"key":"258_CR6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1442-2042.2010.02614.x","volume":"17","author":"H Miyakita","year":"2010","unstructured":"Miyakita H, Yokoyama E, Onodera Y, et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2010;17:869\u201375.","journal-title":"Int J Urol"},{"key":"258_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/iju.12055","volume":"20","author":"T Shirakawa","year":"2013","unstructured":"Shirakawa T, Haraguchi T, Shigemura K, et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. Int J Urol. 2013;20:903\u201310.","journal-title":"Int J Urol"},{"key":"258_CR8","unstructured":"Kissei Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd. Package insert of URIEF\u00ae tab. 2\u00a0mg\/4\u00a0mg and URIEF\u00ae OD tab. 2\u00a0mg\/4\u00a0mg, Seventh Edition [revised Aug 2016] (in Japanese); 2016."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0258-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0258-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0258-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:18:35Z","timestamp":1578010715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0258-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0258-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"3 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The survey was conducted through funding from Kissei Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hiroshi Takahashi, Shinichi Kubono, Takehiko Taneyama, and Kiyotoshi Kuramoto are employees of and hold stock options in Kissei Pharmaceutical Co., Ltd. Hideki Mizutani is an employee of and holds stock options in Daiichi Sankyo Co., Ltd. Noriko Tanaka is an employee of Daiichi Sankyo Co., Ltd. Masaki Yoshida has received grants from Astellas Pharma Inc.; consulting fees from Kyorin Pharmaceutical Co. Ltd. and Kissei Pharmaceutical Co. Ltd.; support for travel to meetings for the study, manuscript preparation and other purposes from Astellas Pharma Inc., Kyorin Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd. and Hisamitsu Pharmaceutical Co. Inc.; fees for participation in review activities from Astellas Pharma Inc., Kyorin Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd. and Hisamitsu Pharmaceutical Co. Inc.; payment for writing or reviewing the manuscript from Astellas Pharma Inc., Kyorin Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd. and Hisamitsu Pharmaceutical Co. Inc.; and payment for lectures, including service on speakers bureaus, from Astellas Pharma Inc., Kyorin Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd. and Hisamitsu Pharmaceutical Co. Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and analysed during the current study are not publicly available because our dataset includes identified individual participants data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This survey was conducted in accordance with good post-marketing study practice in Japan.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"According to good post-marketing study practice in Japan, informed consent was not required for this post-marketing study. As such, informed consent was not obtained from individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}